News Sentiment

GANX sentiment intelligence

Gain Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 65 Constructive news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.80 Week of 10 Jul 2026
Weighted tone 65/100

Constructive news tone

Market reaction Positive news being faded

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update

74/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.8% over one week, +7.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO

Market Reaction

Positive news being faded

74/100 confidence

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update 74/100 classification
One-week reaction -5.8% Price reacting lower
Trend fit Trend inactive 7.1% over four weeks
Fair value -24.3% Below fair value
Sentiment-trend disagreement Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 37
Neutral 14
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Market source 8
Stock Titan 7
Moomoo 5
GlobeNewswire 3
Quartr 3
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 20
Regulatory and legal 8
Analyst action 6

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Stock Titan Direct company coverage

FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial

Gain Therapeutics (NASDAQ: GANX) has received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing it to proceed with Phase 2 clinical development for Parkinson's disease in the U.S. This decision follows positive Phase 1 results that showed fav

Tone
Positive 93/100
Event
Regulatory and legal
Published
29 Jun 2026 19:41
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX

This article provides information about the "Price to earnings forward" for Gain Therapeutics, Inc. (NASDAQ: GANX). It appears to be a financial data point available on TradingView, indicating a specific financial metric for the company. The content itself seems to be a financial

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 15:41
Source
TradingView
Sahm Direct company coverage

3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research

This article highlights three clinical-stage biotech companies, Gain Therapeutics (GANX), MeiraGTx Holdings (MGTX), and Alto Neuroscience (ANRO), that are actively involved in Parkinson's research. It discusses their current clinical progress, market capitalization, revenue, and

Tone
Positive 64/100
Event
Earnings
Published
25 Jun 2026 23:41
Source
Sahm
TradingView Direct company coverage

Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX)

This article provides an overview of Gain Therapeutics, Inc. (NASDAQ:GANX) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and addresses common investor question

Tone
Negative 40/100
Event
Earnings
Published
25 Jun 2026 22:10
Source
TradingView
Stock Titan Direct company coverage

Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting

Gain Therapeutics, Inc. held its annual stockholder meeting on June 24, 2026, where shareholders elected seven directors to one-year terms and ratified Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The director

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:59
Source
Stock Titan
TradingView Direct company coverage

GANX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Gain Therapeutics, Inc. (GANX) stock, including analyst price targets, historical performance, and essential financial data. It highlights that five analysts have offered a 1-year price forecast, with a maximum estimate of $8.00 and a minimum

Tone
Negative 40/100
Event
Analyst action
Published
25 Jun 2026 17:09
Source
TradingView